Description
Identification of therapeutically relevant gene mutations for Myeloid cancerCancer
OncQuer(TM) CML panel
Identification of therapeutically relevant gene mutations for Myeloid cancerCancer
TAT:
Specimen Type:
Genomics Panel Test
Other Tests
-
260%
IGVH Somatic Hyper Mutation Assay
Colon and Lung Cancer marker
-
264%
OncQuer TM Scout LB KRAS Mutation Test
Identification gene mutations leading to resistance to EGFR therapy
OncQuer TM Scout LB KRAS Mutation Test
Identification gene mutations leading to resistance to EGFR therapy
-
264%
NPM-1 Mutation Detection By PCR
Hotspot genes: ABL1, BRAF, CBL, CSF3R, DNMT3A, FLT3, GATA2, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MPL, MYD88, NPM1, NRAS, PTPN11, SETBP1, SF3B1, SRSF2, U2AF1, WT1. Full Genes: ASXL1, BCOR, CALR, CEBPA, ETV6, EZH2, IKZF1, NF1, PHF6, PRPF8, RB1, RUNX1, SH2B3, STAG2, TET2, TP53, ZRSR2. Fusion Driver Genes: ABL1, ALK, BCL2, BRAF, CCND1, CREBBP, EGFR, ETV6 (TEL), FGFR1, FGFR2, FUS, HMGA2, JAK2, KMT2A(MLL), MECOM, MET, MLLT10, MLLT3, MYBL1, MYH11, NTRK3, NUP214, PDGFRA, PDGFRB, RARA, RBM16, RUNX1 (AML1), TCF3(E2A), TFE3
NPM-1 Mutation Detection By PCR
Hotspot genes: ABL1, BRAF, CBL, CSF3R, DNMT3A, FLT3, GATA2, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MPL, MYD88, NPM1, NRAS, PTPN11, SETBP1, SF3B1, SRSF2, U2AF1, WT1. Full Genes: ASXL1, BCOR, CALR, CEBPA, ETV6, EZH2, IKZF1, NF1, PHF6, PRPF8, RB1, RUNX1, SH2B3, STAG2, TET2, TP53, ZRSR2. Fusion Driver Genes: ABL1, ALK, BCL2, BRAF, CCND1, CREBBP, EGFR, ETV6 (TEL), FGFR1, FGFR2, FUS, HMGA2, JAK2, KMT2A(MLL), MECOM, MET, MLLT10, MLLT3, MYBL1, MYH11, NTRK3, NUP214, PDGFRA, PDGFRB, RARA, RBM16, RUNX1 (AML1), TCF3(E2A), TFE3
-
264%
OncQuer TM Germline Mutation Panel by NGS
Identification of gene mutations that increase risk of cancer or has therapeutic implications in an affected individual
OncQuer TM Germline Mutation Panel by NGS
Identification of gene mutations that increase risk of cancer or has therapeutic implications in an affected individual
Reviews
There are no reviews yet.